Review



ki67 low t47d breast cancer cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC ki67 low t47d breast cancer cells
    Ki67 Low T47d Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 6848 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t47d+breast+cancer+cells/T-47D/10__1002_slash_mco2__70783-178-23-50
    Average 99 stars, based on 6848 article reviews
    ki67 low t47d breast cancer cells - by Bioz Stars, 2026-09
    99/100 stars

    Images

    Related Articles

    Multiple Displacement Amplification:

    Article Title: O -GlcNAcylation of epidermal growth factor receptor and glucose transporter 1 prevents their intrinsic down regulation in breast cancer cells.
    Article Snippet: The hexosamine biosynthetic pathway (HBP) is upregulated in many cancer cell types leading to upregulation of posttranslational modification of proteins by β-N-acetylglucosamine (O-GlcNAc), the product of HBP.. However, our knowledge of the identity of proteins that undergo O-GlcNAcylation in cancer cells and consequently their roles is very limited.. We investigated the O-GlcNAcylation of epidermal growth factor receptor (EGFR) and glucose transporter 1 (GLUT1) in T47D and MDA-MB231 breast cancer cell models.

    Cell Culture:

    Article Title: O -GlcNAcylation of epidermal growth factor receptor and glucose transporter 1 prevents their intrinsic down regulation in breast cancer cells.
    Article Snippet: The hexosamine biosynthetic pathway (HBP) is upregulated in many cancer cell types leading to upregulation of posttranslational modification of proteins by β-N-acetylglucosamine (O-GlcNAc), the product of HBP.. However, our knowledge of the identity of proteins that undergo O-GlcNAcylation in cancer cells and consequently their roles is very limited.. We investigated the O-GlcNAcylation of epidermal growth factor receptor (EGFR) and glucose transporter 1 (GLUT1) in T47D and MDA-MB231 breast cancer cell models.

    Article Title: Anti-NME antibody and method of treating cancer or cancer metastasis
    Article Snippet: T47D breast cancer cells were plated and cultured according to ATCC protocols in RPMI media supplemented with serum. .. T47D breast cancer cells were plated and cultured according to ATCC protocols in RPMI media supplemented with serum. ..

    Article Title: Anti-cancer peptide
    Article Snippet: .. T47D breast cancer cells were plated and cultured according to ATCC protocols in RPMI media supplemented with serum. ..

    Article Title: Anti-cancer peptide
    Article Snippet: .. T47D breast cancer cells and DU145 prostate cancer cells were cultured according to recommended protocols by ATCC. ..

    Incubation:

    Article Title: CDK inhibitors
    Article Snippet: .. T47D breast cancer cells from American Type Culture Collection (ATCC, HTB-133) were plated at 3000 cells/well in 96-well plates, and were incubated in RPMI 1640 medium (Gibco, 31800105) with 10% Fetal Bovine Serum (FBS, Biowest, FB-1058) at 37° C., 5% CO2. .. After overnight incubation, baseline values were measured of the samples from one plate using Cyquant reagent (Invitrogen, C35011) following manufacturer's recommendations.

    Article Title: CDK inhibitors
    Article Snippet: The IC50 values of the test compound's anti-proliferation activity were determined from the baseline subtracted viability readout curve using Xlfit5/GraphPad Prism 5 software. .. T47D breast cancer cells from American Type Culture Collection (ATCC, HTB-133) were plated at 40,000 cells/well in 96-well plates, and were incubated in RPMI 1640 medium (Gibco, 31800105) with 10% Fetal Bovine Serum (FBS, Biowest, FB-1058). ..



    Similar Products

    ki67 low t47d breast cancer cells  (ATCC)
    99
    ATCC ki67 low t47d breast cancer cells
    Ki67 Low T47d Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t47d+breast+cancer+cells/T-47D/10__1002_slash_mco2__70783-178-23-50
    Average 99 stars, based on 1 article reviews
    ki67 low t47d breast cancer cells - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    breast cancer cell lines t47d  (ATCC)
    99
    ATCC breast cancer cell lines t47d
    Breast Cancer Cell Lines T47d, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t47d+breast+cancer+cells/T-47D/us12571798-2703-0-13
    Average 99 stars, based on 1 article reviews
    breast cancer cell lines t47d - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    t47d breast cancer cell lines  (ATCC)
    99
    ATCC t47d breast cancer cell lines
    T47d Breast Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t47d+breast+cancer+cells/T-47D/bio_rxiv__64898__2026__01__06__697866-267-2-10
    Average 99 stars, based on 1 article reviews
    t47d breast cancer cell lines - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    human breast cancer cell lines t47d  (ATCC)
    99
    ATCC human breast cancer cell lines t47d
    Human Breast Cancer Cell Lines T47d, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t47d+breast+cancer+cells/T-47D/10__31083_slash_fbl45389-51-0-28
    Average 99 stars, based on 1 article reviews
    human breast cancer cell lines t47d - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    million luciferase mcherry positive t47d breast cancer cells  (ATCC)
    99
    ATCC million luciferase mcherry positive t47d breast cancer cells
    Million Luciferase Mcherry Positive T47d Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t47d+breast+cancer+cells/T-47D/us12491259-992-42-56
    Average 99 stars, based on 1 article reviews
    million luciferase mcherry positive t47d breast cancer cells - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    t47d human breast cancer cell line  (Pasteur Institute)
    86
    Pasteur Institute t47d human breast cancer cell line
    Synergistic cytotoxic effect of 17-AAG-loaded PEG-CS nanoparticles and trastuzumab on <t>T47D</t> cells. Cell viability was assessed by MTT assay after 72 h of treatment. Data are presented as mean ± SD ( n = 3). The combination group (17-AAG-loaded NPs + trastuzumab) showed significantly reduced cell viability (15%) compared to treatment with 17-AAG-loaded NPs alone (50%), trastuzumab alone (35%), or blank NPs + trastuzumab (100%). Statistical significance: **** p < 0.0001 vs. Blank NPs + Trastuzumab group (one-way ANOVA with Tukey’s post-hoc test). The Combination Index (CI) calculated using CompuSyn software was 0.72, indicating strong synergy.
    T47d Human Breast Cancer Cell Line, supplied by Pasteur Institute, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t47d+breast+cancer+cells/7+mcf/pmc12783725-25-1-11
    Average 86 stars, based on 1 article reviews
    t47d human breast cancer cell line - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    tumour breast cancer cell lines t47d  (ATCC)
    99
    ATCC tumour breast cancer cell lines t47d
    Synergistic cytotoxic effect of 17-AAG-loaded PEG-CS nanoparticles and trastuzumab on <t>T47D</t> cells. Cell viability was assessed by MTT assay after 72 h of treatment. Data are presented as mean ± SD ( n = 3). The combination group (17-AAG-loaded NPs + trastuzumab) showed significantly reduced cell viability (15%) compared to treatment with 17-AAG-loaded NPs alone (50%), trastuzumab alone (35%), or blank NPs + trastuzumab (100%). Statistical significance: **** p < 0.0001 vs. Blank NPs + Trastuzumab group (one-way ANOVA with Tukey’s post-hoc test). The Combination Index (CI) calculated using CompuSyn software was 0.72, indicating strong synergy.
    Tumour Breast Cancer Cell Lines T47d, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t47d+breast+cancer+cells/T-47D/pmc12574668-32-19-29
    Average 99 stars, based on 1 article reviews
    tumour breast cancer cell lines t47d - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Synergistic cytotoxic effect of 17-AAG-loaded PEG-CS nanoparticles and trastuzumab on T47D cells. Cell viability was assessed by MTT assay after 72 h of treatment. Data are presented as mean ± SD ( n = 3). The combination group (17-AAG-loaded NPs + trastuzumab) showed significantly reduced cell viability (15%) compared to treatment with 17-AAG-loaded NPs alone (50%), trastuzumab alone (35%), or blank NPs + trastuzumab (100%). Statistical significance: **** p < 0.0001 vs. Blank NPs + Trastuzumab group (one-way ANOVA with Tukey’s post-hoc test). The Combination Index (CI) calculated using CompuSyn software was 0.72, indicating strong synergy.

    Journal: Scientific Reports

    Article Title: Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2 + breast cancer

    doi: 10.1038/s41598-025-30507-2

    Figure Lengend Snippet: Synergistic cytotoxic effect of 17-AAG-loaded PEG-CS nanoparticles and trastuzumab on T47D cells. Cell viability was assessed by MTT assay after 72 h of treatment. Data are presented as mean ± SD ( n = 3). The combination group (17-AAG-loaded NPs + trastuzumab) showed significantly reduced cell viability (15%) compared to treatment with 17-AAG-loaded NPs alone (50%), trastuzumab alone (35%), or blank NPs + trastuzumab (100%). Statistical significance: **** p < 0.0001 vs. Blank NPs + Trastuzumab group (one-way ANOVA with Tukey’s post-hoc test). The Combination Index (CI) calculated using CompuSyn software was 0.72, indicating strong synergy.

    Article Snippet: The T47D human breast cancer cell line was obtained from the Pasteur Institute of Iran.

    Techniques: MTT Assay, Software

    In vitro cytotoxicity of 17-AAG-loaded PEG-CS NPs in T47D and MDA-MB-231 cells. Cell viability after 72 h treatment with free 17-AAG or 17-AAG-loaded NPs. The nanoformulation showed significantly enhanced cytotoxicity, with an IC₅₀ of 2.3 ± 0.3 µM in T47D cells, representing a threefold increase compared to free 17-AAG (IC₅₀ = 6.9 ± 0.5 µM). Similar results were observed in MDA-MB-231 cells (IC₅₀ = 3.0 µM for NPs vs. 8.1 µM for free drug). Blank PEG-CS NPs showed no significant toxicity in NHDF cells (up to 50 µg/mL). Data are mean ± SEM ( n = 3). Statistical significance was determined by one-way ANOVA followed by Tukey’s post-hoc test. **** P < 0.0001 vs. control.

    Journal: Scientific Reports

    Article Title: Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2 + breast cancer

    doi: 10.1038/s41598-025-30507-2

    Figure Lengend Snippet: In vitro cytotoxicity of 17-AAG-loaded PEG-CS NPs in T47D and MDA-MB-231 cells. Cell viability after 72 h treatment with free 17-AAG or 17-AAG-loaded NPs. The nanoformulation showed significantly enhanced cytotoxicity, with an IC₅₀ of 2.3 ± 0.3 µM in T47D cells, representing a threefold increase compared to free 17-AAG (IC₅₀ = 6.9 ± 0.5 µM). Similar results were observed in MDA-MB-231 cells (IC₅₀ = 3.0 µM for NPs vs. 8.1 µM for free drug). Blank PEG-CS NPs showed no significant toxicity in NHDF cells (up to 50 µg/mL). Data are mean ± SEM ( n = 3). Statistical significance was determined by one-way ANOVA followed by Tukey’s post-hoc test. **** P < 0.0001 vs. control.

    Article Snippet: The T47D human breast cancer cell line was obtained from the Pasteur Institute of Iran.

    Techniques: In Vitro, Control

    Flow cytometric analysis of apoptosis in T47D cells after 24 h treatment with 17-AAG-loaded PEG-CS NPs. A Untreated control cells. B Cells treated with 17-AAG-loaded PEG-CS NPs. The percentage of apoptotic cells (Q2 + Q3) increased from 16.5% in the control group to 52.2% in the treated group. Data are representative of three independent experiments ( n = 3).

    Journal: Scientific Reports

    Article Title: Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2 + breast cancer

    doi: 10.1038/s41598-025-30507-2

    Figure Lengend Snippet: Flow cytometric analysis of apoptosis in T47D cells after 24 h treatment with 17-AAG-loaded PEG-CS NPs. A Untreated control cells. B Cells treated with 17-AAG-loaded PEG-CS NPs. The percentage of apoptotic cells (Q2 + Q3) increased from 16.5% in the control group to 52.2% in the treated group. Data are representative of three independent experiments ( n = 3).

    Article Snippet: The T47D human breast cancer cell line was obtained from the Pasteur Institute of Iran.

    Techniques: Control

    Cell cycle distribution in T47D cells after 24 h treatment with 17-AAG-loaded PEG-CS NPs. The treated group showed an increase in the G2/M phase (26.50%) compared to control (19.30%), indicating G2/M arrest. Data are representative of three independent experiments ( n = 3).

    Journal: Scientific Reports

    Article Title: Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2 + breast cancer

    doi: 10.1038/s41598-025-30507-2

    Figure Lengend Snippet: Cell cycle distribution in T47D cells after 24 h treatment with 17-AAG-loaded PEG-CS NPs. The treated group showed an increase in the G2/M phase (26.50%) compared to control (19.30%), indicating G2/M arrest. Data are representative of three independent experiments ( n = 3).

    Article Snippet: The T47D human breast cancer cell line was obtained from the Pasteur Institute of Iran.

    Techniques: Control

    qRT-PCR analysis of HSP90 and β-actin gene expression in T47D cells after 72 h treatment with 17-AAG-loaded PEG-CS NPs. A Melting curves for HSP90 (Tm = 78.2 °C) and β-actin (Tm = 83.9 °C), showing single sharp peaks that confirm the specificity of amplification and absence of primer-dimers. Data are representative of three independent experiments ( n = 3). B Amplification curves for HSP90 (purple line) and β-actin (blue line) genes, showing the cycle threshold (Ct) values used for relative quantification of gene expression.

    Journal: Scientific Reports

    Article Title: Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2 + breast cancer

    doi: 10.1038/s41598-025-30507-2

    Figure Lengend Snippet: qRT-PCR analysis of HSP90 and β-actin gene expression in T47D cells after 72 h treatment with 17-AAG-loaded PEG-CS NPs. A Melting curves for HSP90 (Tm = 78.2 °C) and β-actin (Tm = 83.9 °C), showing single sharp peaks that confirm the specificity of amplification and absence of primer-dimers. Data are representative of three independent experiments ( n = 3). B Amplification curves for HSP90 (purple line) and β-actin (blue line) genes, showing the cycle threshold (Ct) values used for relative quantification of gene expression.

    Article Snippet: The T47D human breast cancer cell line was obtained from the Pasteur Institute of Iran.

    Techniques: Quantitative RT-PCR, Gene Expression, Amplification, Quantitative Proteomics